Greater abundance of immune cells within the Trp53−/− Brca1−/− TME makes this tumour model ideal for anti-PD-L1 treatment, as the highly abundant immune cells will be able to continuously eliminate cancer cells without being inhibited [44, 45]. This evidence concerns the gene CD274 and neoplasm.